Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation

Recruiting now

Conditions studied: Lung Cancer (Diagnosis), Nodule, Solitary Pulmonary

In brief

The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule. Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.

Key facts

Study ID

NCT07623473

Run by

Herlev and Gentofte Hospital

People needed

1800

Starts

2024-05-22

Expected to finish

2028-02-01

Last updated by the study team

2026-06-03

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit
• Having signed informed consent

You may not qualify if…

• Active cancer, excluding non-melanoma skin cancer
• Comorbidities that exclude the patient from clinical follow-up and final diagnosis

Where it is running

• Gentofte Hospital — Gentofte Municipality, Denmark (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.